Mounjaro, Popular Weight-Loss Drug, Launched in India – Price, Benefits, and More
US-based pharmaceutical company Eli Lilly has launched its popular anti-diabetes and weight-loss drug Mounjaro in India. The launch follows marketing authorization from the Central Drugs Standard Control Organisation (CDSCO), India’s drug regulator.
Mounjaro is a once-a-week prescription medicine that helps manage blood sugar levels and controls appetite. It is now available in India as a single-dose vial.
💊 What is Mounjaro Used For?
Mounjaro contains tirzepatide, the active ingredient that activates two key hormones:
✅ GIP (Glucose-dependent Insulinotropic Polypeptide)
✅ GLP-1 (Glucagon-like Peptide-1)
These hormones help regulate blood sugar and reduce food intake, making it effective for:
🔹 Adults with obesity (BMI of 30 or more)
🔹 Overweight adults (BMI of 27 or more) with weight-related health conditions
🔹 Adults with type 2 diabetes to control blood sugar levels
💰 Mounjaro Price in India
The pricing of Mounjaro in India is based on the dosage:
🔹 2.5 mg single-dose vial – ₹3,500
🔹 5 mg injection – ₹4,375
🔹 Monthly treatment cost (2.5 mg starting dose) – ₹14,000
🔬 Clinical Trial Results: Effective for Weight Loss and Diabetes Control
Mounjaro has shown impressive results in global clinical trials:
✅ SURMOUNT-1 (Weight Loss Study)
In a study of 2,539 adults with obesity:
- At the highest dose (15 mg) – Patients lost an average of 21.8 kg over 72 weeks
- At the lowest dose (5 mg) – Patients lost an average of 15.4 kg
- In comparison, people on a placebo lost only 3.2 kg
✅ SURPASS (Diabetes Control Study)
In this study, Mounjaro was tested with other diabetes medicines.
- It lowered blood sugar (A1C) levels by up to 2.4% over 40 weeks
⚙️ How Does Mounjaro Work?
Mounjaro is designed to:
🔹 Stimulate insulin release to control blood sugar
🔹 Reduce glucagon levels (a hormone that raises blood sugar)
🔹 Improve insulin sensitivity
🔹 Slow digestion, making people feel full longer
🔹 Reduce food intake and fat storage
📊 India’s Growing Diabetes and Obesity Crisis
India has around 101 million people living with diabetes, with nearly 50% lacking proper blood sugar control. Obesity is a major risk factor, affecting over 100 million Indians and contributing to high blood pressure, heart disease, and sleep disorders.
🏥 Expert Insights
Winselow Tucker, President of Lilly India, emphasized the importance of bringing innovative medicines to India.
“Our goal is to help people with obesity and diabetes live healthier lives. The launch of Mounjaro is part of our commitment to offering innovative treatment options,” he said.
Dr. Manish Mistry, Senior Medical Director at Eli Lilly India, added:
“Obesity and diabetes can lead to serious health complications. Mounjaro offers a new and effective treatment for managing these conditions.”
✅ Final Thoughts
The launch of Mounjaro in India offers a new and effective treatment option for patients battling obesity and type 2 diabetes. With its once-a-week dosage, strong clinical trial results, and the potential to improve overall health, Mounjaro could become a game-changer in diabetes and weight management.
🔹 Price: ₹3,500 per vial (2.5 mg)
🔹 Treatment cost: ₹14,000/month (starting dose)
🔹 Availability: Prescription-based, recommended by healthcare professionals
Stay informed about the latest health updates and breakthroughs! 🩺💊
Reference from:-https://www.indiatoday.in/health/story/widely-popular-anti-diabetes-drug-mounjaro-tirzepatide-zepbound-eli-lilly-launched-india-2696237-2025-03-20